目的 研究羌活胜湿汤对风湿外感头痛患者的疗效。方法 选择2018年1月—2020年12月我院收治的62例风湿外感头痛患者,随机分为2组。对照组服用5 mg的氟桂利嗪胶囊,每晚1次;观察组联用羌活胜湿汤。比较2组风湿外感头痛患者的有效率,治疗前后的睡眠质量评分和视觉模拟评分法(VAS)评分。结果 观察组风湿外感头痛患者的有效率(96.77%)高于对照组(80.64%) (P<0.05);治疗前,2组风湿外感头痛患者的VAS评分无差异(P>0.05),治疗后,2组风湿外感头痛患者的VAS评分降低(P<0.05),且观察组风湿外感头痛患者的VAS评分更低(P<0.05);治疗前,2组风湿外感头痛患者的夜间苏醒、入睡时间、睡眠深度、早醒、白天情绪、梦境情况、气色和白天身体状况评分无差异(P>0.05),治疗后,2组风湿外感头痛患者的夜间苏醒、入睡时间、睡眠深度、早醒、白天情绪、梦境情况、气色和白天身体状况评分降低(P<0.05),且观察组风湿外感头痛患者的夜间苏醒、入睡时间、睡眠深度、早醒、白天情绪、梦境情况、气色和白天身体状况评分低于对照组(P<0.05)。结论 羌活胜湿汤对风湿外感头痛患者有显著的疗效,与其能明显减轻疼痛程度和改善睡眠质量有关。

Objective To investigate the effect of Qianghuo Shengshi decoction on patients with wind-damp headache. Methods A total of 62 cases of patients with wind-damp headache who were treated in our hospital from January 2018 to December 2020 were selected and divided into two groups randomly. The control group took 5 mg of flunarizine capsules once a night; the observation group took Qianghuo Shengshi decoction additionally. The effective rate, sleep quality score and visual analogue scale(VAS) score before and after treatment were compared between the two groups of patients. Results The effective rate of the observation group (96.77%) was significantly higher than that of the control group (80.64%, P<0.05). Before treatment, the VAS scores of the two groups of patients with exogenous wind-damp headache were not significantly different (P>0.05). After treatment, the VAS scores of the two groups were significantly reduced (P<0.05), and the score drop of the observation group was significant (P<0.05). Before treatment, there were no significant differences in night awakening, sleep time, sleep depth, early awakening, daytime mood, dream condition, complexion and daytime physical condition score between the two groups (P>0.05), after treatment, the scores of night awakening, sleep time, sleep depth, early awakening, daytime mood, dream condition, complexion and daytime physical condition in patients with wind-damp headache in both groups were significantly decreased (P<0.05), and the scores of night awakening, sleep time, sleep depth, early awakening, daytime mood, dream condition, complexion and daytime physical condition in patients with wind-damp headache in the observation group were significantly lower than those in the control group (P<0.05). Conclusions Qianghuo Shengshi decoction had a significant effect on patients with wind-damp headache, and its was related to its ability of significant pain reduction and sleep quality improvement.

目的 探讨急性脑梗死采用丹红联合曲克芦丁脑蛋白水解物治疗的效果。方法 本文将2019年7月—2020年9月我院收治的88例急性脑梗死患者作为研究对象,应用简单数字表达法将患者随机分为两组,44例对照组和44例实验组,对照组患者应用丹红注射液治疗,实验组患者则在对照组基础上联合曲克芦丁脑蛋白水解物进行治疗,1个疗程后,统计分析用药后有效率、治疗前后NIHSS评分、血液流变学指标。结果 两组之间治疗后NIHSS评分、血液流变学指标相比,实验组较对照组低;用药后有效率相比,实验组较对照组高,P＜0.05。结论 采用丹红注射液治疗急性脑梗死的基础上给予曲克芦丁脑蛋白水解物治疗可提升疗效,改善患者神经功能缺损状态与血液循环,改善患者预后,促进患者早日康复。

Objective To investigate the effect of Danhong combined with troxerutin brain protein hydrolysate in the treatment of acute cerebral infarction. Methods 88 patients with acute cerebral infarction in our hospital from July 2019 to September 2020 were randomly divided into two groups, 44 cases in the control group and 44 cases in the experimental group. The effective rate, NIHSS score and hemorheology indexes before and after treatment were statistically analyzed after one course of treatment. Results After treatment, NIHSS score and hemorheology indexes of the experimental group were lower than those of the control group; the effective rate of the experimental group was higher than that of the control group, P<0.05. Conclusion On the basis of Danhong injection in the treatment of acute cerebral infarction, troxerutin cerebroprotein hydrolysate can improve the curative effect, improve the neurological deficit and blood circulation, improve the prognosis of patients, and promote the early recovery of patients.

目的 观察早期经鼻肠内营养(ENEN)对中-重度急性胰腺炎(MSAP+SAP)患者的治疗效果。方法 回顾性分析2014年9月—2019年5月期间,广东药科大学附属第一医院消化内科收治的50例MSAP及SAP患者临床资料,根据患者营养支持治疗方式不同,将患者分为观察组(n=25)和对照组(n=25)。观察组患者采用ENEN治疗,对照组采用肠外肠内营养联合(PNEN)治疗。对比两组患者治疗后血清白蛋白(ALB)、血清前白蛋白(PA)、C-反应蛋白(CRP)、急性生理与慢性健康(APACHE Ⅱ)评分、序贯器官功能衰竭(SOFA)评分及多器官功能障碍综合征(MODS)发生率。结果 经过治疗后,观察组患者ALB水平、PA水平高于对照组,CRP水平低于对照组,差异有统计学意义(P＜0.05)。经过治疗后,观察组患者APACHE Ⅱ评分、SOFA评分低于对照组,差异有统计学意义(P＜0.05)。经过治疗后,观察组患者MODS发生率低于对照组,差异有统计学意义(P＜0.05)。结论 ENEN治疗MSAP及SAP患者可有效改善患者营养状态和健康状况,降低机体炎症反应,减少MODS发生率。

Objective To observe the effect of early nasal enteral nutrition(ENEN) on patients with moderate to severe acute pancreatitis(MSAP+SAP). Methods A retrospective analysis of the clinical data of 58 patients with(MSAP+SAP) admitted to the department of gastroenterology, the First Affiliated Hospital of Guangdong Pharmaceutical University from September 2014 to May 2019, according to the different nutritional support treatment methods, the patients were divided into observation groups(n=25) and control group(n=25). Patients in the observation group were treated with ENEN, and the control group was treated with Parenteral nutrition and enteral nutrition(PNEN). Serum albumin(ALB), serum prealbumin(PA), C-reactive protein(CRP), acute physiology and chronic health evaluation(APACHE II) score, sequential organ failure assessment(SOFA) score, and incidence of multiple organ dysfunction syndrome(MODS) were compared between the two groups. Results After treatment, the ALB and PA level of the observation group were higher than those of the control group, and the CRP level was lower than that of the control group, the difference was statistically significant(P<0.05). After treatment, the APACHE II score and SOFA score of the observation group were lower than those of the control group, and the difference was statistically significant(P<0.05). After treatment, the incidence of MODS in the observation group was lower than that in the control group, and the difference was statistically significant(P<0.05). Conclusion ENEN treatment of MSAP and SAP may effectively improve the nutritional status and health of patients, reduce the body's inflammatory response and reduce the incidence of MODS.

目的 研究纤维支气管镜下给药治疗耐多药空洞型肺结核的临床治疗效果。方法 抽取我院2017年1月—2019年12月期间收治的空洞型肺结核耐多药(同时耐INH、RFP,其他药敏试验抗痨药物均敏感)患者74例作为研究对象,其中38例设作治疗组,在应用传统抗痨药物帕司烟肼、EMB、PZA、TH1321治疗基础上,应用纤维支气管镜下给药治疗,药物选择AMK和左氧氟沙星;36例设作对照组,单纯应用传统抗结核药物帕司烟肼、EMB、PZA、TH1321治疗,比较两组临床治疗效果。结果 治疗组临床治疗总有效率94.7%,高于对照组66.7%,两组比较差异有统计学意义(P＜0.05);治疗后,两组QOL评分均高于治疗前,治疗组评分高于对照组,比较差异有统计学意义(P＜0.05);治疗组患者痰菌转阴时间、病灶减少时间、空洞缩小时间等指标均优于对照组,比较差异有统计学意义(P＜0.05);两组不良反应比较无差异(P＞0.05)。结论 纤维支气管镜下给药应用AMK和左氧氟沙星,可以有效治疗耐多药空洞型肺结核,取得理想的临床治疗效果,能有效改善患者临床症状,缩短痰菌转阴、病灶减少和空洞缩小的时间,有效改善患者的生活质量,而且治疗安全性较高,可以应用于临床推广。

Objective To study the clinical effect of drug administration under fiberoptic bronchoscope in the treatment of multi drug resistant (mdr) cavitary pulmonary tuberculosis. Methods 74 patients with cavitary pulmonary tuberculosis(who were resistant to INH and RFP at the same time and sensitive to other drugs in other drug sensitivity tests) were selected as the study subjects. 38 of them were set up as the treatment group. On the basis of the treatment with traditional antituberculosis drugs such as pasiazide, EMB, PZA and TH1321, they were treated with fiberoptic bronchoscopy and drug selection AMK and levofloxacin, 36 cases as control group, were treated with traditional antituberculotic drugs, such as pasiazide, EMB, PZA and TH1321. Results The total effective rate of clinical treatment in the treatment group was 94.7%, higher than 66.7% in the control group, and the difference between the two groups was statistically significant(P<0.05);there was no difference in adverse reactions between the two groups(P>0.05). Conclusion Administration of AMK and levofloxacin under fiberbronchoscope may effectively treat mdr-cavitary tuberculosis, achieve ideal clinical treatment effect, effectively improve the clinical symptoms of patients, shorten the time of sputum bacteria turning negative, focus reduction and cavitary reduction, effectively improve the quality of life of patients. The treatment safety is high, which may be applied in clinical promotion.

目的 分析并探讨应用通窍活血汤配合舒血宁注射液在治疗糖尿病视网膜病变(单纯型)中的临床效果。方法 80例患者(80只眼)按照随机的方式将其列入对照组(40只眼)和治疗组(40只眼)两组,对照组给以调节血糖、饮食控制、运动疗法等常规治疗控制血糖稳定并口服通窍活血汤,治疗组在对照组的基础上,口服通窍活血汤再配合舒血宁注射液离子导入,所有患者均由同一位眼科专科医生分别在治疗前后对所选患者行眼压、视力、眼底镜检查,同时观察其治疗前后血液流变学、血脂变化情况,观察治疗效果。结果 治疗前后血糖、糖化血红蛋白改变无差异,治疗组视力、眼底均较对照组明显改善(P＜0.01),血液流变学,血及血脂各指标的改善较对照组比较有统计学意义(P＜0.01)。结论 通窍活血汤配合舒血宁注射液在单纯型糖尿病视网膜病变中的治疗效果显著,可有明显改善患者的血脂及血液流变学,安全可靠,适合临床长期推广应用,具有较高的社会效益和经济效益,值得临床推广应用。

目的 观察吉西他滨联合萘达铂治疗铂类敏感复发性卵巢癌的近期疗效与不良反应。方法 回顾性分析潍坊市人民医院2013年1月—2014年6月治疗的60例复发性卵巢癌病例,分为吉西他滨联合萘达铂(GN)方案化疗组30例和吉西他滨联合卡铂(GC)方案化疗组30例。GN方案组,吉西他滨1.0 g/m²,d1、8;萘达铂80 mg/m²,d1,21d为1周期;GC方案组,吉西他滨1.0 g/m²,d1、8;卡铂按AUC=5计算,d1,21 d为1周期。结果 GN方案组近期有效率56.0%,GC方案组近期有效率60.0%,两组比较差异无统计学意义(χ² =0.069,P=0.793)。两组最常见的毒性反应均是骨髓抑制,GC组骨髓抑制发生率较GN组骨髓抑制发生率稍高,但两组比较差异无统计学意义(P>0.05)。结论 两种方案治疗铂类敏感型复发性卵巢癌疗效无统计学差异,GN方案组不良反应较轻。

Objective To evaluate the clinical effect of GN chemotherapy protocol and GC chemotherapy protocol treatment of recurrent ovarian cancers. Methods We retrospectively analyzed the data of 60 patients with recurrent ovarian cancers in our hospital from January 2013 to June 2014. Divided into gemcitabine and nedaplatin (GN)chemotherapy group and Gemcitabine and carboplatin(GC)chemotherapy group, 30 patients in each group.Patients in GP protocol group were given Gemcitabine 1.0 g/m²,d1,8;and naphthalene(80 mg/m²,d1),21d was a period of treatment; Patients in GC protocol group were given gemcitabine 1.0 g/m²,d1,8;and carboplatin AUC=5 by calculation,21d was a period of treatment. Results For patients in GN protocol group,the short term response rate was 56.0%.For patients in GC protocol group,the short term response rate was 60.0%,the difference was not statistically significant(χ²=0.069,P=0.793). Two of the most common toxicities were myelosuppression, incidence of myelosuppression GC was slightly higher than GN, and the difference was not statistically significant. Conclusion The therapeutic effects of two chemotherapy protocols have no statistically significant difference in treatment of platinum sensitive recurrent ovarian cancer. Toxicity of GN group is light.

目的 观察肌内效贴联合物理治疗急性踝关节扭伤的临床疗效。方法 将52例急性踝关节扭伤患者随机均分为肌内效贴联合物理治疗组(观察组)和常规物理治疗组(对照组),分别于治疗前及治疗后第5、10天时观察患部肿胀程度和VAS评分及踝关节kofoed评分。结果 治疗后第5、10天时两组肿胀程度和VAS评分较治疗前好转(P＜0.05),kofoed评分较治疗前升高(P＜0.05)。观察组在肿胀改善、VAS评分及kofoed评分方面均优于对照组(P＜0.05)。结论 肌内效贴联合物理治疗改善急性踝关节伤患者临床症状,改善踝关节功能,临床疗效优于单纯物理治疗。

Objective The purpose of this pilot study was to investigate the effectiveness of kinesio taping combined with conventional physiotherapy for acute ankle sprain patients. Methods 52 acute ankle sprain patients were randomly divided into kinesio taping combined with conventional physiotherapy group(observation group) and the conventional physiotherapy group(control group),and to observe the changes of the affected part of swelling and the visual analogue scale(VAS)and the extent of the ankle joint function recovery situation at the fifth day and the tenth day respectively. Results Two groups suffering from swelling part and the VAS was improved after the treatment at the fifth day and the tenth day (P<0.05), and the ankle kofoed scores were increased too (P<0.05). The observation group in improving the swelling, VAS and kofoed score were significantly better than the control group (P< 0.05). Conclusion Kinesio taping combined with conventional physiotherapy can be a more effective therapeutic technique for treating acute ankle sprain.

       目的 评价不同间变性淋巴瘤激酶（ALK）抑制剂联合安罗替尼治疗非小细胞肺癌（NSCLC）的疗效。方法 收集ALK突变阳性NSCLC患者的临床资料，筛选服用ALK抑制剂疗效不佳再加用安罗替尼的病例。根据不同的用药方案分为阿来替尼+安罗替尼，塞瑞替尼+安罗替尼和克唑替尼+安罗替尼三个组别。记录患者联合用药前最近一次的影像学检查结果，并以此为基线按Recist1.1评价疗效，以病情进展、患者死亡、停药、改变治疗方案为终点计算各组患者的无事件生存期（EFS），收集肿瘤标志物、血常规和肝功、心功能、肾功能生化检测等指标数据，统计分析患者联合用药前后各项指标的变化。结果 经筛选，共纳入49例患者的临床数据。阿来替尼+安罗替尼组有23例，疾病控制率（DCR）为86.96%；平均EFS为（10.8±3.6）个月，中位EFS为8.3个月；塞瑞替尼+安罗替尼组有14例，DCR为71.43%；平均EFS为（6.5±2.9）个月，中位EFS为5.6个月；克唑替尼+安罗替尼组有12列，DCR为66.67%；平均EFS为（7.7±3.2）个月，中位EFS为7.2个月。阿来替尼+安罗替尼组的平均EFS长于另外两组（P＜0.05）。各研究组肿瘤标志物仅有CyFra21-1在克唑替尼+安罗替尼组在联合用药后升高（P＜0.05），生化检测和血常规指标在用药前后差异无统计学意义（P＞0.05）。结论  ALK抑制剂与安罗替尼联用，疗效最好为阿来替尼，其次为塞瑞替尼，最后为克唑替尼。三种ALK抑制剂与安罗替尼联用后，均未导致心、肝、肾功能和血细胞损害。

      Objective  To evaluate the efficacy of different anaplastic lymphoma kinase（ALK）inhibitors combined with anlotinib in the treatment of non-small cell lung cancer（NSCLC）．Methods  Clinical data of drug resistant NSCLC patients with ALK positive mutation was collected who were treated with ALK inhibitors and anlotinib synchronously．According to different regimens，three groups were set，alectinib+anlotinib，ceritinib+anlotinib，and crizotinib+anlotinib．The latest imageological examination  results of the patient before the synchronous therapy was set as the baseline to evaluate the therapeutic effect according to Recist1.1．The event free survival（EFS）of each group was calculated with disease progression，patient death，treatment discontinuation and changing regimen as endpoints．Data of tumor markers，hematology test，liver function，cardiac function，renal function biochemical examination was collected and analyzed statistically before and after the combination therapy，with P＜0.05 as the statistically significant difference．Results  After screening，clinical data of 49 patients were collected．Twenty-three patients in the alectinib+anlotinib group，with a disease control rate（DCR） of 86.96%；mean EFS was（10.8±3.6）months，median EFS of 8.3 months；14 patients in the ceritinib+anlotinib group，with a DCR of 71.43%，mean EFS was（6.5±2.9）months，median EFS was 5.6 months；12 patients in the crizotinib+anlotinib group，with a DCR of 66.67%，mean EFS was（7.7±3.2）months，median EFS was 7.2 months．EFS of alectinib+anlotinib group was longer significantly than the other two groups（P＜0.05）．Only CyFra21-1，increased significantly after the combination of crizotinib and anlotinib（P＜0.05）．No statistically significant difference in biochemical test and hematology test before and after the treatment（P＞0.05）．Conclusions  The therapeutic effect of ALK inhibitors with anlotinib was ordered，alectinib being the most effective，followed by ceritinib and finally crizotinib．The combination of ALK inhibitors with anlotinib did not cause any abnormal results in the examination of heart，liver，kidney and blood cells．